Author: admin

Nasopharyngeal Carcinoma Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | BeiGene, Coherus, Harbour BioMed, Innovent Biologics, Junshi Biosciences, Novartis

“Delveinsight Business Research LLP”
As per DelveInsight’s assessment, the Nasopharyngeal Carcinoma therapeutics market is anticipated to grow in the coming years owing to the rise in the number of cases of Nasopharyngeal Carcinoma, the increase in the R&D activities, the development & launch of targeted products and immunotherapies with better efficacy.

DelveInsight’s “Nasopharyngeal Carcinoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Nasopharyngeal Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Nasopharyngeal Carcinoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Nasopharyngeal Carcinoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Nasopharyngeal Carcinoma: An Overview

Nasopharyngeal Cancer is a type of head and neck cancer that affects the part of the throat connecting the back of the nose to the back of the mouth (nasopharynx). It should not be confused with other types of cancer affecting the throat, such as laryngeal and oesophageal cancer.

Most nasopharyngeal cancers are nasopharyngeal carcinoma (NPC). There are three types of NPC. They all start from epithelial cells that line the nasopharynx, but the cells of each type look different under a microscope. Three types include non-keratinizing undifferentiated carcinoma, non-keratinizing differentiated carcinoma, and keratinizing squamous cell carcinoma.

The exact cause of nasopharyngeal cancer is unknown, but a number of factors can increase your risk of developing the condition, which includes being of South Chinese or North African descent, having a diet very high in salt-cured meats and fish, being exposed to the Epstein-Barr virus (EBV).

This type of cancer can be treated with a multidisciplinary approach. The main treatment option is radiation therapy, however, it is often given in combination with chemotherapy. This approach may be called concomitant chemoradiotherapy.

Surgery for NPC is occasionally used, mainly to remove lymph nodes after chemoradiotherapy or to treat NPC that has come back after initial treatment. Palliative therapy is also used to control the symptoms related to cancer and its treatment. Chemotherapy is also the option of choice when distant metastasis is involved. NPC with distant poly-metastasis is offered palliative chemotherapy. The agents of choice are cisplatin and 5-fluorouracil. With recent advances, several chemotherapeutic agents are available for the continuation of therapy.

Nasopharyngeal Carcinoma Market Key Facts

  • According to the National Health Services (NHS), nasopharyngeal cancer affects men about 3 times more than women.

  • According to the American Cancer Society, about half of the people with nasopharyngeal cancer in the United States are younger than 55 years old, and the average age at diagnosis is about 50.

  • As per the data by Globocan, approximately 133,300+ people were affected by nasopharynx cancer across the globe in 2020; the United States accounted for 1,890+ incident cases of nasopharynx carcinoma.

  • Some of the key players in the therapeutic market include Tessa Therapeutics, BeiGene, Innovent Biologics (Suzhou), Novartis Pharmaceuticals, Jiangsu HengRui, Harbour BioMed, and others.

  • The expected launch of emerging therapies such as TT10, Tislelizumab, and others for treating Nasopharyngeal Cancers shall fuel the market size growth in the upcoming years.

  • The dynamics of the Nasopharyngeal Cancer market are anticipated to change in the coming year. Some of the key players are actively working in the therapeutic market to improve the Nasopharyngeal Carcinoma treatment scenario. The emerging therapeutics treatment options in Nasopharyngeal Cancer Landscape are more focused on developing targeted products and immunotherapies for better efficacy.

Nasopharyngeal Carcinoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Nasopharyngeal Carcinoma pipeline therapies. It also thoroughly assesses the Nasopharyngeal Carcinoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Nasopharyngeal Carcinoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Nasopharyngeal Carcinoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Nasopharyngeal Carcinoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Nasopharyngeal Carcinoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Nasopharyngeal Carcinoma Epidemiology, Segmented as –

  • Total Incidence of Nasopharyngeal Cancer in the 7MM (2019-2032)

  • Treated Pool of Nasopharyngeal Cancer (total NPC patient pool including recurrent cases) in the 7MM (2019-2032)

  • Age-specific Incidence of Nasopharyngeal Cancer in the 7MM (2019-2032)

  • Stage-wise Incidence of Nasopharyngeal Cancer in the 7MM (2019-2032)

  • Gender-specific Incidence of Nasopharyngeal Cancer in the 7MM (2019-2032)

  • Recurrent/Metastatic Incidence of Nasopharyngeal Cancer in the 7MM (2019-2032)

Nasopharyngeal Carcinoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Nasopharyngeal Carcinoma market or expected to be launched during the study period. The analysis covers the Nasopharyngeal Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Nasopharyngeal Carcinoma drugs based on their sale and market share.

The report also covers the Nasopharyngeal Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Nasopharyngeal Carcinoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Nasopharyngeal Carcinoma Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/nasopharyngeal-carcinoma-market

Nasopharyngeal Carcinoma Therapeutics Analysis

The treatment options and recommendations for nasopharyngeal cancer depend on several factors, including the type and stage of cancer, possible side effects, and the patient’s preferences and overall health. The approach is mainly multidisciplinary several professional works together and make decisions, known as shared decision-making. It is particularly important for nasopharyngeal cancer because there are different treatment options.

Chemotherapy is used in different situations to treat nasopharyngeal cancer like it can be often used together with radiation therapy as the first treatment for more advanced stages of nasopharyngeal cancer because some chemodrugs make cancer cells more sensitive to radiation. It may also be given after radiation as an adjuvant treatment. Common chemo drugs that are used in the treatment of nasopharyngeal cancer include carboplatin (PARAPLATIN), Doxorubicin (ADRIAMYCIN), epirubicin (ELLENCE), paclitaxel (TAXOL), docetaxel (TAXOTERE), gemcitabine (GEMZAR), bleomycin, methotrexate.

In targeted therapies, ERBITUX (cetuximab) is mainly used in the treatment of nasopharyngeal cancer. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Nasopharyngeal cancer cells sometimes have more than normal amounts of EGFR, which can help them grow faster. By blocking EGFR, cetuximab may slow or stop this growth.

In immunotherapies, mainly KEYTRUDA and OPDIVO are used, which are PD-1 inhibitors. It can be used after chemotherapy and these are mainly used in metastatic cancer. A number of companies are evaluating immunotherapies in combination with PD1/PDL1 inhibitors for the treatment of head and neck cancers, including nasopharyngeal cancer. The use of immunotherapy for recurrent nasopharyngeal carcinoma patients is an active area of clinical research.

Nasopharyngeal Carcinoma Companies Actively Working in the Therapeutics Market Include

  • Atara Biotherapeutics

  • BeiGene

  • Coherus

  • Harbour BioMed

  • Innovent Biologics (Suzhou)

  • Jiangsu HengRui

  • Junshi Biosciences

  • Novartis Pharmaceuticals

  • Tessa Therapeutics

And Many Others

Emerging and Marketed Nasopharyngeal Carcinoma Therapies Covered in the Report Include:

  • Tislelizumab: BieGene

  • Tabelecleucel plus Keytruda: Atara Biotherapeutics

  • PDR001: Novartis

  • Toripalimab: Junshi Biosciences/ Coherus

  • HBM9167: Harbour BioMed

  • TT10: Tessa Therapeutics

  • Sintilimab: Innovent Biologics

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/nasopharyngeal-carcinoma-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Nasopharyngeal Carcinoma Competitive Intelligence Analysis

4. Nasopharyngeal Carcinoma Market Overview at a Glance

5. Nasopharyngeal Carcinoma Disease Background and Overview

6. Nasopharyngeal Carcinoma Patient Journey

7. Nasopharyngeal Carcinoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Nasopharyngeal Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Nasopharyngeal Carcinoma Unmet Needs

10. Key Endpoints of Nasopharyngeal Carcinoma Treatment

11. Nasopharyngeal Carcinoma Marketed Therapies

12. Nasopharyngeal Carcinoma Emerging Drugs and Latest Therapeutic Advances

13. Nasopharyngeal Carcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Nasopharyngeal Carcinoma Market Outlook (In US, EU5, and Japan)

16. Nasopharyngeal Carcinoma Companies Active in the Market

17. Nasopharyngeal Carcinoma Access and Reimbursement Overview

18. KOL Views on the Nasopharyngeal Carcinoma Market

19. Nasopharyngeal Carcinoma Market Drivers

20. Nasopharyngeal Carcinoma Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/nasopharyngeal-carcinoma-market

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Endometrial Cancer Market

“Endometrial Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Endometrial Cancer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Endometrial Cancer market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nasopharyngeal Carcinoma Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | BeiGene, Coherus, Harbour BioMed, Innovent Biologics, Junshi Biosciences, Novartis

ER+/ HER2 -ve Breast Cancer Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | BeiGene, AstraZeneca, CytomX, Sanofi, Eli Lilly, EQRx, Gilead, Roche

“Delveinsight Business Research LLP”
As per DelveInsight, the ER+/ HER2 -ve Breast Cancer Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases and the launch of new therapies in the market.

DelveInsight’s “ER+/ HER2 -ve Breast Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the ER+/ HER2 -ve Breast Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging ER+/ HER2 -ve Breast Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current ER+/ HER2 -ve Breast Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

ER+/ HER2 -ve Breast Cancer: An Overview

ER+ (estrogen receptor-positive) and HER2- (human epidermal growth factor receptor 2-negative) breast cancer signifies a specific subtype of breast cancer characterized by the presence of estrogen receptors on the surface of cancer cells but an absence of HER2 protein overexpression. This subtype accounts for a significant proportion of breast cancer diagnoses. Symptoms of ER+/HER2- breast cancer are similar to other breast cancer types, such as a lump or thickening in the breast, changes in breast size or shape, nipple changes, or skin dimpling. Diagnosis involves a series of tests including mammograms, ultrasounds, MRIs, and biopsies to confirm the cancer type and stage.

Treatment for ER+/HER2- breast cancer often involves a multidisciplinary approach. Hormone therapies like tamoxifen or aromatase inhibitors are typically employed to target estrogen receptors, blocking their activity or reducing estrogen levels in the body. Surgery (lumpectomy or mastectomy), radiation therapy, and chemotherapy might be recommended based on the stage and aggressiveness of the cancer. 

The burden of ER+/HER2- breast cancer is significant due to its prevalence and the necessity for long-term treatments, potentially leading to significant emotional, physical, and financial strains on patients and healthcare systems. Research continues to explore targeted therapies and personalized medicine approaches to improve treatment outcomes and reduce the burden on individuals affected by this breast cancer subtype. Early detection through screenings and advancing treatment options are critical in addressing the growing burden of ER+/HER2- breast cancer and improving survival rates.

ER+/ HER2 -ve Breast Cancer Market Key Facts

  • The total market size of ER+/HER2− Breast Cancer in the United States is USD 6,759 million in 2021 and is projected to grow during the forecast period (2022-2032).

  • The total market size of ER+/HER2− Breast Cancer in first-line settings in the United States is USD 3,471 million in 2021

  • The total incident population of Breast Cancer in the United States is 256,431 in 2021.

  • In the United States, more cases were observed for postmenopausal Breast Cancer, with 205,145 cases in 2021.

  • In 2021, cases of the localized, regional, distant, and unknown stages were observed to be 164,116, 74,365, 15,386, and 2,564 respectively. This number might increase during the forecast period.

  • Among the various subtypes of the disease (localized and regional), ER+/HER2− occupies the maximum patient pool, with 147,977 cases of this category, followed by the number of those with 24,325 cases of Triple-negative and 20,271 cases of ER+/HER2+. On the other hand, HR−/HER2+ accommodated the least number of cases.

ER+/ HER2 -ve Breast Cancer Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging ER+/ HER2 -ve Breast Cancer pipeline therapies. It also thoroughly assesses the ER+/ HER2 -ve Breast Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed ER+/ HER2 -ve Breast Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

ER+/ HER2 -ve Breast Cancer Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted ER+/ HER2 -ve Breast Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted ER+/ HER2 -ve Breast Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the ER+/ HER2 -ve Breast Cancer Epidemiology, Segmented as –

  • Total incident population of Breast Cancer

  • Incidence of Breast Cancer cases by menopausal status

  • Stage-specific incidence of Breast Cancer

  • Subtype-specific incidence of Breast Cancer

  • Treatment eligible pool for localized and metastatic Breast Cancer

ER+/ HER2 -ve Breast Cancer Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the ER+/ HER2 -ve Breast Cancer market or expected to be launched during the study period. The analysis covers the ER+/ HER2 -ve Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the ER+/ HER2 -ve Breast Cancer drugs based on their sale and market share.

The report also covers the ER+/ HER2 -ve Breast Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key ER+/ HER2 -ve Breast Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the ER+/ HER2 -ve Breast Cancer Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market

ER+/ HER2 -ve Breast Cancer Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for ER+/ HER2-VE Breast Cancer. Currently, Astrazeneca is leading the therapeutics market with its ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage of clinical development.

ER+/ HER2 -ve Breast Cancer Companies Actively Working in the Therapeutics Market Include

BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, Radius Pharmaceuticals, Sanofi, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and many others.

Emerging and Marketed ER+/ HER2 -ve Breast Cancer Therapies Covered in the Report Include:

  • AZD9833: Astrazeneca

  • BGB-290: BeiGene

  • IBRANCE (palbociclib): Pfizer

  • AFINITOR (everolimus): Novartis

  • Elacestrant: Radius Pharmaceuticals

  • Giredestrant (RG6171, GDC-9545): Roche

  • Camizestrant (AZD9833): AstraZeneca

  • LY3484356 (imlunestrant): Eli Lilly

  • Lerociclib (EQ132): EQRx

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. ER+/ HER2 -ve Breast Cancer Competitive Intelligence Analysis

4. ER+/ HER2 -ve Breast Cancer Market Overview at a Glance

5. ER+/ HER2 -ve Breast Cancer Disease Background and Overview

6. ER+/ HER2 -ve Breast Cancer Patient Journey

7. ER+/ HER2 -ve Breast Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. ER+/ HER2 -ve Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. ER+/ HER2 -ve Breast Cancer Unmet Needs

10. Key Endpoints of ER+/ HER2 -ve Breast Cancer Treatment

11. ER+/ HER2 -ve Breast Cancer Marketed Therapies

12. ER+/ HER2 -ve Breast Cancer Emerging Drugs and Latest Therapeutic Advances

13. ER+/ HER2 -ve Breast Cancer Seven Major Market Analysis

14. Attribute Analysis

15. ER+/ HER2 -ve Breast Cancer Market Outlook (In US, EU5, and Japan)

16. ER+/ HER2 -ve Breast Cancer Companies Active in the Market

17. ER+/ HER2 -ve Breast Cancer Access and Reimbursement Overview

18. KOL Views on the ER+/ HER2 -ve Breast Cancer Market

19. ER+/ HER2 -ve Breast Cancer Market Drivers

20. ER+/ HER2 -ve Breast Cancer Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Retinoblastoma Market

“Retinoblastoma Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Retinoblastoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Retinoblastoma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ER+/ HER2 -ve Breast Cancer Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | BeiGene, AstraZeneca, CytomX, Sanofi, Eli Lilly, EQRx, Gilead, Roche

Chronic Lymphocytic Leukemia Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Astex, BeiGene, MorphoSys, Celgene, Cellectar, Gilead, Incyte, IO Biotech, Janssen

“Delveinsight Business Research LLP”
As per DelveInsight, the Chronic Lymphocytic Leukemia Market is anticipated to evolve immensely in the coming years owing to the rapid adoption of the sedentary lifestyle, increasing aging population, improvement in the diagnosis technologies, incremental healthcare spending across the world, increasing incidence of CLL and the launch of the emerging novel therapies.

DelveInsight’s “Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Lymphocytic Leukemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Chronic Lymphocytic Leukemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Lymphocytic Leukemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic Lymphocytic Leukemia: An Overview

Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL) is an indolent malignancy characterized by increased production of mature but dysfunctional B lymphocytes. CLL and SLL are identical from a pathologic and immunophenotypic standpoint. Both CLL and SLL originate from B-cell lymphocytes, but present with different manifestations depending on where the abnormal cells are found. Usually, the initial leukemic phase represents CLL, where the cells are present in the blood. This eventually progresses to the lymphoma phase, representing SLL, where the cells are found in the lymph nodes.

CLL/SLL is defined as a monoclonal lymphoproliferative disease characterized by the proliferation and accumulation of morphologically mature but immunologically dysfunctional B-cell lymphocytes The primary disease sites include peripheral blood, spleen, lymph nodes, and bone marrow.

The exact etiology of Chronic Lymphocytic Leukemia is unknown. Genetic factors, rather than environmental factors, are the most likely cause of Chronic Lymphocytic Leukemia. However, a few known risk factors for Chronic Lymphocytic Leukemia include occupational causes by exposure to certain chemicals, radiation exposure, and tobacco users.

Chronic Lymphocytic Leukemia Market Key Facts

  • According to Surveillance, Epidemiology, and End Results (SEER), the rate of new cases of chronic lymphocytic leukemia was 4.7 per 100,000 men and women per year. These rates are age-adjusted and based on 2015-2019 cases and 2016-2020 deaths.

  • According to Kajuter et al. 2021, The age-standardized incidence rate is four to five cases per 100,000 person-years, and about 5500 patients in Germany are newly diagnosed with Chronic Lymphocytic Leukemia annually. Men are more often affected than women.

  • According to Cancer Research UK, Over the last decade, chronic lymphocytic leukemia incidence rates have increased by around a tenth (9%) in the UK. Rates in females have remained stable, and rates in males have increased by more than a twentieth (7%) (2015-2017).

  • According to Quinquenel et al. 2020, in 2018, the estimated number of new incident cases of Chronic Lymphocytic Leukemia in France was 4674. The male predominance is marked, with 59.3% of Chronic Lymphocytic Leukemia cases identified in men (2770 patients) and 40.7% of cases identified in women (1904 patients).4 The median age at diagnosis is 71 years in men and 73 years in women.

  • On January 19, 2023, the U.S. Food and Drug Administration (FDA) granted approval to BeiGene’s Brukinsa (Zanubrutinib), a Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Chronic Lymphocytic Leukemia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Lymphocytic Leukemia pipeline therapies. It also thoroughly assesses the Chronic Lymphocytic Leukemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Chronic Lymphocytic Leukemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Chronic Lymphocytic Leukemia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Chronic Lymphocytic Leukemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chronic Lymphocytic Leukemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Chronic Lymphocytic Leukemia Epidemiology, Segmented as –

  • Total Incidence of Chronic Lymphocytic Leukemia in the 7MM (2019-2032)

  • Age-specific Incidence of Chronic Lymphocytic Leukemia in the 7MM (2019-2032)

  • Treatable Cases of Chronic Lymphocytic Leukemia in the 7MM (2019-2032)

  • Gender-specific Incidence of Chronic Lymphocytic Leukemia in the 7MM (2019-2032)

  • Relapsed and Refractory Cases of Chronic Lymphocytic Leukemia in the 7MM (2019-2032)

Chronic Lymphocytic Leukemia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Lymphocytic Leukemia market or expected to be launched during the study period. The analysis covers the Chronic Lymphocytic Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chronic Lymphocytic Leukemia drugs based on their sale and market share.

The report also covers the Chronic Lymphocytic Leukemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chronic Lymphocytic Leukemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Chronic Lymphocytic Leukemia Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/chronic-lymphocytic-leukemia-cll-market

Chronic Lymphocytic Leukemia Therapeutics Analysis

The available treatment options for Chronic Lymphocytic Leukemia (CLL) vary depending on the patient’s age, disease risk group, and the displayed symptoms. The goal of treatment for the patient is the induction of remission and prolonging life while minimizing treatment-related adverse effects. There is an exception for allogeneic hematopoietic stem cell transplantation (HSCT), none of the current therapies are considered curative, but a subset of patients experiences long-term remissions.

Looking at the treatment options CLL has seen a significant evolution in the past decades. The historical standard of initial chemotherapy with chlorambucil has been largely replaced with more effective chemoimmunotherapy regimens incorporating monoclonal antibodies (mAbs) targeting CD20 (rituximab [Rituxan], obinutuzumab [Gazyva], and ofatumumab [Arzerra]), and targeted therapy with the small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), ibrutinib (Imbruvica). 

Several major pharma and biotech companies are developing therapies for chronic lymphocytic leukemia. Currently, Loxo Oncology is leading the therapeutics market with its chronic lymphocytic leukemia drug candidates in the most advanced stage of clinical development.

Chronic Lymphocytic Leukemia Companies Actively Working in the Therapeutics Market Include

AFA Insurance, Astex Pharmaceuticals, BeiGene, Bristol Myers Squibb, Celgene, Cellectar Biosciences, Inc., Gilead Sciences, Incyte Corporation, IO Biotech, Janssen Research & Development, LLC, Loxo Oncology, MorphoSys AG, Novartis, Octapharma, Oncternal Therapeutics, TG Therapeutics, TG therapeutics, Zhejiang DTRM Biopharma, and many others.

Emerging and Marketed Chronic Lymphocytic Leukemia Therapies Covered in the Report Include:

  • Olaptesed pegol: NOXXON Pharma

  • Zanubrutinib: BeiGene

  • KTE-X19: Kite, a Gilead Company

  • Ublituximab: TG Therapeutics

  • LOXO305: Loxo Oncology

  • Cirmtuzumab: Oncternal Therapeutics

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/chronic-lymphocytic-leukemia-cll-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Chronic Lymphocytic Leukemia Competitive Intelligence Analysis

4. Chronic Lymphocytic Leukemia Market Overview at a Glance

5. Chronic Lymphocytic Leukemia Disease Background and Overview

6. Chronic Lymphocytic Leukemia Patient Journey

7. Chronic Lymphocytic Leukemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Chronic Lymphocytic Leukemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Lymphocytic Leukemia Unmet Needs

10. Key Endpoints of Chronic Lymphocytic Leukemia Treatment

11. Chronic Lymphocytic Leukemia Marketed Therapies

12. Chronic Lymphocytic Leukemia Emerging Drugs and Latest Therapeutic Advances

13. Chronic Lymphocytic Leukemia Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Lymphocytic Leukemia Market Outlook (In US, EU5, and Japan)

16. Chronic Lymphocytic Leukemia Companies Active in the Market

17. Chronic Lymphocytic Leukemia Access and Reimbursement Overview

18. KOL Views on the Chronic Lymphocytic Leukemia Market

19. Chronic Lymphocytic Leukemia Market Drivers

20. Chronic Lymphocytic Leukemia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/chronic-lymphocytic-leukemia-cll-market

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Febrile Neutropenia Market

“Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Febrile Neutropenia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Febrile Neutropenia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Lymphocytic Leukemia Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Astex, BeiGene, MorphoSys, Celgene, Cellectar, Gilead, Incyte, IO Biotech, Janssen

Becker Muscular Dystrophy Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Italfarmaco, Immunoforge, Edgewise Therapeutics, Epirium Bio, Ultragenyx, Strykagen

“Delveinsight Business Research LLP”
As per DelveInsight, the Becker Muscular Dystrophy Market is anticipated to evolve immensely in the coming years owing to the rise in the number of prevalent cases and the launch of new therapies in the market.

DelveInsight’s “Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Becker Muscular Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Becker Muscular Dystrophy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Becker Muscular Dystrophy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Becker Muscular Dystrophy: An Overview

Becker Muscular Dystrophy (BMD) is an inherited muscle structure disorder that results in progressive deterioration of limbs, and cardiac and skeletal muscles. However, the involuntary muscles are not affected. BMD is a milder version of Duchenne Muscular Dystrophy (DMD). BMD usually begins in the teens or early adulthood, and the course is slower and far less predictable than that of DMD.

Early symptoms of BMD are cramps after exercising, and later in life, the person begins to experience problems while walking quickly or running. Other noticeable symptoms besides weakness are falling, feeling “worn out,” and changes in the skeletal system. Muscle weakness often affects the legs and pelvis, and slowly gets worse. Few affected individuals even have learning problems, but these cases are typically minor.

BMD is caused due to a deformity of the DMD gene, which is an X-linked disorder (therefore, females are the carriers of this defect). This abnormality in the gene produces defective dystrophin protein. This protein helps stabilize and protect muscle fibers and may play a role in chemical signaling within cells. Muscle cells without fully functional dystrophin become damaged as muscles contract and relax with use. They then weaken and die over time, leading to muscle weakness and heart problems in people with BMD.

BMD primarily affects males. However, the age of onset and rate of progression can vary. Muscle weakness usually becomes apparent between the ages of 5–15. In some cases, heart involvement (cardiomyopathy) can also be the first sign of BMD. This form of heart disease weakens the cardiac muscle, preventing the heart from pumping blood efficiently. Cardiomyopathy typically begins in adolescence and later, the heart muscle becomes enlarged, and the heart problems develop into a condition known as dilated cardiomyopathy.

Becker Muscular Dystrophy Market Key Facts

  • According to the Genetic and Rare Diseases Information Center, the prevalence of Becker Muscular Dystrophy is estimated to be between 17–27 cases per million people. This means that at a given time, about one in 37,000 to one in 59,000 people are living with Becker Muscular Dystrophy.

  • According to the Centers for Disease Control and Prevention (CDC), the estimated prevalence of Duchenne and Becker muscular dystrophy (Becker Muscular Dystrophy) was one in every 7,250 males aged 5–24 years. However, the prevalence of DMD was found to be three times higher than the prevalence of Becker Muscular Dystrophy.

  • According to a study conducted by Walter et al. (2017), titled “Recent developments in Duchenne muscular dystrophy: facts and numbers”, the worldwide prevalence of Becker Muscular Dystrophy is estimated to be 1.53 per 100,000 males and according to recent calculations of the German population, about 600 Becker Muscular Dystrophy patients are supposed to live in Germany.

Becker Muscular Dystrophy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Becker Muscular Dystrophy pipeline therapies. It also thoroughly assesses the Becker Muscular Dystrophy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Becker Muscular Dystrophy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Becker Muscular Dystrophy Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Becker Muscular Dystrophy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Becker Muscular Dystrophy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Becker Muscular Dystrophy Epidemiology, Segmented as –

  • Prevalent Cases of Becker Muscular Dystrophy

  • Age-specific Prevalent Cases of Becker Muscular Dystrophy

  • Diagnosed and Treatable Cases of Becker Muscular Dystrophy

Becker Muscular Dystrophy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Becker Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the Becker Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Becker Muscular Dystrophy drugs based on their sale and market share.

The report also covers the Becker Muscular Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Becker Muscular Dystrophy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Becker Muscular Dystrophy Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/becker-muscular-dystrophy-market

Becker Muscular Dystrophy Therapeutics Analysis

The treatment of BMD focuses on lessening the symptoms associated with it. There is no cure, but treatments are available to help with symptoms and maximize muscle function. It is vital that a person with BMD stay in shape and continue to use their muscles. Though there are no FDA-approved drugs for the treatment of BMD, but many different therapies are currently under investigation for its treatment.

Medications that lessen the overall workload of the heart are sometimes prescribed for BMD. Evidence suggests that treatment with angiotensin-converting enzyme (ACE) inhibitors and beta blockers can slow the course of cardiac muscle deterioration in BMD if the medications are started as soon as abnormalities appear on an echocardiogram (imaging of the heart), but before symptoms occur.

Several major pharma and biotech companies are developing therapies for Becker Muscular Dystrophy. Currently, Italfarmaco is leading the therapeutics market with its Becker Muscular Dystrophy drug candidates in the most advanced stage of clinical development.

Becker Muscular Dystrophy Companies Actively Working in the Therapeutics Market Include

  • Italfarmaco

  • Immunoforge Co., Ltd.

  • Edgewise Therapeutics

  • Epirium Bio

  • Ultragenyx

  • Strykagen

And Many Others

Emerging and Marketed Becker Muscular Dystrophy Therapies Covered in the Report Include:

  • Givinostat: Italfarmaco – Givinostat (INN) or gavinostat (originally ITF2357) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Since Givinostat acts on the pathogenetic events downstream of the genetic defects, it is potentially a treatment for the whole DMD and BMD population and to counter the disease pathogenetic events in all muscular districts. The drug is currently being evaluated in Phase II clinical to treat Becker muscular dystrophy.

  • EDG-5506: Edgewise Therapeutics – Edgewise Therapeutics Continued to advance a Phase I MAD study of EDG-5506, a small molecule drug candidate designed to arrest muscle fiber breakdown in Duchenne and Becker muscular dystrophy (DMD and BMD).

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/becker-muscular-dystrophy-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Becker Muscular Dystrophy Competitive Intelligence Analysis

4. Becker Muscular Dystrophy Market Overview at a Glance

5. Becker Muscular Dystrophy Disease Background and Overview

6. Becker Muscular Dystrophy Patient Journey

7. Becker Muscular Dystrophy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Becker Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Becker Muscular Dystrophy Unmet Needs

10. Key Endpoints of Becker Muscular Dystrophy Treatment

11. Becker Muscular Dystrophy Marketed Therapies

12. Becker Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances

13. Becker Muscular Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Becker Muscular Dystrophy Market Outlook (In US, EU5, and Japan)

16. Becker Muscular Dystrophy Companies Active in the Market

17. Becker Muscular Dystrophy Access and Reimbursement Overview

18. KOL Views on the Becker Muscular Dystrophy Market

19. Becker Muscular Dystrophy Market Drivers

20. Becker Muscular Dystrophy Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/becker-muscular-dystrophy-market

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market

“Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the CDKL5 market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Becker Muscular Dystrophy Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Italfarmaco, Immunoforge, Edgewise Therapeutics, Epirium Bio, Ultragenyx, Strykagen

Metastatic Renal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023

DelveInsight’s, “Metastatic Renal Cell Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Metastatic Renal Cell Carcinoma pipeline landscape. It covers the Metastatic Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Renal Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report

  • DelveInsight’s Metastatic Renal Cell Carcinoma pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Metastatic Renal Cell Carcinoma treatment.
  • The leading companies working in the Metastatic Renal Cell Carcinoma Market include AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co. Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd, and others.
  • Promising Metastatic Renal Cell Carcinoma Pipeline Therapies in the various stages of development include Nivolumab, Ipilimumab, Sunitinib, Pazopanib, Tc 99m EC20, AGS-16C3F, Axitinib, and others.
  • December 2023: Ipsen announced a study of Phase 2 clinical trials for Cabozantinib. The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
  • December 2023: Hoffmann-La Roche announced a study of Phase 2 clinical trials for Tobemstomig, Tiragolumab, Pembrolizumab and Axitinib. This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

 

Request a sample and discover the recent advances in Metastatic Renal Cell Carcinoma Treatment Drugs @ Metastatic Renal Cell Carcinoma Pipeline Outlook Report

 

In the Metastatic Renal Cell Carcinoma pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Metastatic Renal Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Metastatic Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Metastatic Renal Cell Carcinoma Overview

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 85% of neoplasms arising from the kidney. Renal cell carcinoma may remain clinically occult for most of its course. Only 10% of patients present with the classic triad of flank pain, hematuria, and flank mass. Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases.

 

Find out more about Metastatic Renal Cell Carcinoma Therapeutics Assessment @ Metastatic Renal Cell Carcinoma Preclinical and Discovery Stage Products

 

Metastatic Renal Cell Carcinoma Emerging Drugs Profile

  • Olaparib: AstraZeneca
  • Atezolizumab: Genentech
  • TP-1454: Sumitomo Dainippon Pharma

 

Metastatic Renal Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the Metastatic Renal Cell Carcinoma therapies. The Metastatic Renal Cell Carcinoma companies which have their Metastatic Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Genentech.

 

DelveInsight’s Metastatic Renal Cell Carcinoma pipeline report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Metastatic Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Metastatic Renal Cell Carcinoma Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Learn more about the emerging Metastatic Renal Cell Carcinoma Pipeline Therapies @ Metastatic Renal Cell Carcinoma Clinical Trials Assessment

 

Scope of the Metastatic Renal Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Metastatic Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Metastatic Renal Cell Carcinoma Companies- AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co. Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd, and others.
  • Metastatic Renal Cell Carcinoma Pipeline Therapies- Nivolumab, Ipilimumab, Sunitinib, Pazopanib, Tc 99m EC20, AGS-16C3F, Axitinib, and others.

 

Dive deep into rich insights for new drugs for Metastatic Renal Cell Carcinoma Treatment, Visit @ Metastatic Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Renal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Atezolizumab: Genentech
  9. Drug profiles in the detailed report…..
  10. Mid-Stage Products (Phase II)
  11. Olaparib: AstraZeneca
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. TP-1454: Sumitomo Dainippon Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Renal Cell Carcinoma Key Companies
  21. Metastatic Renal Cell Carcinoma Key Products
  22. Metastatic Renal Cell Carcinoma- Unmet Needs
  23. Metastatic Renal Cell Carcinoma- Market Drivers and Barriers
  24. Metastatic Renal Cell Carcinoma- Future Perspectives and Conclusion
  25. Metastatic Renal Cell Carcinoma Analyst Views
  26. Metastatic Renal Cell Carcinoma Key Companies
  27. Appendix

 

For further information on the Metastatic Renal Cell Carcinoma Pipeline therapeutics, reach out to Metastatic Renal Cell Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Renal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023

Mesothelioma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023

DelveInsight’s, “Mesothelioma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Mesothelioma pipeline landscape. It covers the Mesothelioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mesothelioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Mesothelioma Pipeline Report

  • DelveInsight’s Mesothelioma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Mesothelioma treatment.
  • The leading companies working in the Mesothelioma Market include Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor Inc., NGM Biopharmaceuticals Inc., Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others.
  • Promising Mesothelioma Pipeline Therapies in the various stages of development include Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Pembrolizumab, IAG933, Volrustomig, Carboplatin, and others.
  • December 2023: PrECOG LLC announced a study of Phase 3 clinical trials for Durvalumab. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with PM.
  • December 2023: AstraZeneca announced a study of Phase 3 clinical trials for Volrustomig, Pemetrexed, Carboplatin and Cisplatin. This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator’s choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

 

Request a sample and discover the recent advances in Mesothelioma Treatment Drugs @ Mesothelioma Pipeline Outlook Report

 

In the Mesothelioma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Mesothelioma NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Mesothelioma Overview

Mesothelioma is a cancer caused by asbestos. It most commonly occurs in the linings of the lungs or the abdomen. The average life expectancy is 18 – 31 months after diagnosis, but prognosis may improve with treatment. Symptoms can include chest pain, shortness of breath and general fatigue.

 

Find out more about Mesothelioma Therapeutics Assessment @ Mesothelioma Preclinical and Discovery Stage Products

 

Mesothelioma Emerging Drugs Profile

  • MesoPher: Amphera
  • Durvalumab: AstraZeneca

 

Mesothelioma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Mesothelioma therapies. The Mesothelioma companies which have their Mesothelioma drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

 

DelveInsight’s Mesothelioma pipeline report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Mesothelioma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Mesothelioma Pipeline Therapies @ Mesothelioma Clinical Trials Assessment

 

Scope of the Mesothelioma Pipeline Report

  • Coverage- Global
  • Mesothelioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Mesothelioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Mesothelioma Companies- Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor Inc., NGM Biopharmaceuticals Inc., Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others.
  • Mesothelioma Pipeline Therapies- Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Pembrolizumab, IAG933, Volrustomig, Carboplatin, and others.

 

Dive deep into rich insights for new drugs for Mesothelioma Treatment, Visit @ Mesothelioma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Mesothelioma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Mesothelioma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Mesothelioma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Durvalumab: AstraZeneca
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. TRC102: TRACON Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. SG001: CSPC ZhongQi Pharmaceutical Technology
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Mesothelioma Key Companies
  23. Mesothelioma Key Products
  24. Mesothelioma- Unmet Needs
  25. Mesothelioma- Market Drivers and Barriers
  26. Mesothelioma- Future Perspectives and Conclusion
  27. Mesothelioma Analyst Views
  28. Mesothelioma Key Companies
  29. Appendix

 

For further information on the Mesothelioma Pipeline therapeutics, reach out to Mesothelioma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mesothelioma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023

Hollywood Lace Elevates the Standard with the Rated #1 Most Natural Hair Systems of 2023

Unveiling Hollywood Lace: Setting the Gold Standard in Undetectable Hair Systems.

Los Angeles – Dec 12, 2023 – Hollywood Lace, the industry leader in premium hair systems, proudly announces its latest achievement as the Rated #1 Most Natural Hair Systems of 2023 by the prestigious Mitchell Hair Institute. This recognition underscores Hollywood Lace’s commitment to excellence, setting new standards in undetectable hair solutions.

The Mitchell Hair Institute, renowned for its authoritative hair industry evaluations, has honored Hollywood Lace for its ground-breaking advancements in creating 100% undetectable hairlines. The key to Hollywood Lace’s success lies in its proprietary techniques, including single-strand staggered ventilation, root bleaching, and color capping. These innovations seamlessly blend with natural hair, ensuring a lifelike appearance that is second to none.

“We are thrilled to be recognized as the industry leader by the Mitchell Hair Institute,” said the CEO of Hollywood Lace. “Our commitment to providing the most natural-looking hair systems has always been at the forefront of our brand. This acknowledgment validates our dedication to innovation and quality in the ever-evolving world of hair replacement.”

Unlike other hair replacement companies that compromise on quality, Hollywood Lace refuses to cut corners, ensuring clients receive the authentic and natural look they desire. Hollywood Lace’s award-winning hair systems stand out for their unparalleled quality, providing customers with an undetectable and confidence-boosting solution.

While Hollywood Lace acknowledges that its products may not be the cheapest on the market, the brand emphasizes that they are the epitome of quality. Investing in a Hollywood Lace hair system guarantees a genuine, natural appearance worth every penny.

To celebrate this prestigious recognition and to extend gratitude to new clients, Hollywood Lace is offering an exclusive discount. First-time customers can enjoy a 20% discount using coupon code 1STHL20 during checkout. This limited-time offer allows individuals to experience the Hollywood Lace difference at an even more accessible price point.

 

Hollywood Lace continues revolutionizing the hair replacement industry, combining artistry, innovation, and quality craftsmanship. The Rated #1 Most Natural Hair Systems of 2023 accolade reinforces Hollywood Lace’s position as a frontrunner in providing top-tier, undetectable hair solutions.

About Hollywood Lace

Hollywood Lace is a leading provider of premium hair systems, committed to delivering undetectable and natural-looking solutions to individuals seeking high-quality hair replacement. With a focus on innovation and craftsmanship, Hollywood Lace has earned recognition as the #1 Most Natural Hair Systems of 2023 by the Mitchell Hair Institute.

For media inquiries or to learn more about Hollywood Lace and its award-winning hair systems, please get in touch with them.

Media Contact
Company Name: Holllywood Lace (A division of Swiss Lace Direct)
Contact Person: William Richter
Email: Send Email
Country: United States
Website: Hollywoodlace.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hollywood Lace Elevates the Standard with the Rated #1 Most Natural Hair Systems of 2023

Stanislav Kondrashov Telf AG: new strategic trends at the ArcelorMittal plant

One of the world’s largest steel production plants, ArcelorMittal, was formed through the merger of two giants – Arcelor and Mittal Steel in 2006. The company now has factories in more than 60 countries with its head office in Luxembourg. According to an expert in the field of metallurgy, Stanislav Kondrashov, ArcelorMittal not only produces steel, but also plays a key role in the development of many industries, from construction to automotive manufacturing, in different countries.

ArcelorMittal is reviewing its strategy – Stanislav Kondrashov

According to the expert, in recent years ArcelorMittal has been actively focusing on innovation and sustainable development. The company invests in developing new technologies to reduce carbon emissions and improve resource efficiency.

ArcelorMittal has successfully adapted to global economic challenges, including the COVID-19 pandemic, market volatility and political changes.

  • Optimizing production processes, closing unprofitable factories and searching for new markets are all part of the company’s strategy to maintain its leading position,– Stanislav Kondrashov from Telf AG notes.

The company recently announced the suspension of operations at its Zenica plant in Bosnia and the possible closure of its Resende mini-plant in Brazil. These moves reflect structural changes in the global steel industry.

Stanislav Kondrashov: suspension of Zenica Resende factories. What is the reason?

The Bosnian plant Zenica, which produced up to 700 thousand tons of products per year, stopped the smelting of iron and steel. The Omarska mining and processing plant, the main supplier of iron ore for this plant, is also likely to cease operations. Stanislav Kondrashov names several reasons for this decision: the worsening situation on the European market, increased competition from Turkish steel producers in the Balkans, a significant increase in energy, raw materials and other costs.

The specialist notes that since 2020, workers’ wages have increased by 32%, but the quality of the mined ore has deteriorated – the iron content has decreased from 53% to 47%. This situation increases production costs and reduces the competitiveness of products.

ArcelorMittal may start up the Zenica plant if the market situation improves. However, the exact timing of the resumption of production has not been determined, and forecasts for the beginning of 2024 remain not the most encouraging.

In Brazil, according to Stanislav Kondrashov from Telf AG, the situation is similar. The ArcelorMittal Resende mini-factory in the state of Rio de Janeiro, specializing in the production of fittings and wire rods, may be closed due to declining domestic demand, rising costs and competition from imported products. Steel imports into Brazil in the ten months of 2023 increased by 74% compared to the previous year, reaching 3.105 million tons.

  • ArcelorMittal, like many in the global steel industry, faces a number of challenges: rising costs, increased competition and changes in the global economy. These factors require rethinking strategies and adapting to new market realities. The closure of factories in Bosnia and Brazil is a signal that the industry faces serious challenges that will shape the situation in the coming years, – Stanislav Kondrashov from Telf AG sums up.

He believes that a shift to more sustainable manufacturing practices, adaptation to changing demand and constant innovation will shape the company’s path in the coming years.

Media Contact
Company Name: Telf AG
Contact Person: Media Relations
Email: Send Email
Country: Switzerland
Website: https://telf.ch/

HR Positive/ HER2 Negative Breast Cancer Pipeline, Clinical Trials Developments and Companies 2023

DelveInsight’s, “HR Positive/ HER2 Negative Breast Cancer Pipeline Insights 2023” report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape. It covers the HR Positive/ HER2 Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HR Positive/ HER2 Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the HR Positive/ HER2 Negative Breast Cancer Pipeline Report

  • DelveInsight’s HR Positive/ HER2 Negative Breast Cancer pipeline report depicts a robust space with 50+ active players working to develop 53+ pipeline therapies for HR Positive/ HER2 Negative Breast Cancer treatment.
  • The leading companies working in the HR Positive/ HER2 Negative Breast Cancer Market include Regor Therapeuics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co. Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche, and others.
  • Promising HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies in the various stages of development include CX-2009, CX-072, Dato-DXd, Capecitabine, Gemcitabine, OP-1250, Ribociclib, Alpelisib, Palbociclib 125mg, Cyclophosphamide, Doxorubicin, and others.
  • December 2023: AstraZeneca announced a study of Phase 3 clinical trials for AZD9833, Anastrozole, and Letrozole. The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
  • December 2023: Hofmann-La Roche announced a study of Phase 3 clinical trials for Inavolisib, Fulvestrant and Alpelisib. This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based therapy.
  • December 2023: Novartis Pharmaceuticals announced a study of Phase 3 clinical trials for Ribociclib, Letrozole, Alpelisib and Fulvestrant. The purpose of this clinical trial is to study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole and, in patients with a PIK3CA mutation, on second-line treatment with alpelisib plus fulvestrant.

 

Request a sample and discover the recent advances in HR Positive/ HER2 Negative Breast Cancer Treatment Drugs @ HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report

 

In the HR Positive/ HER2 Negative Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, HR Positive/ HER2 Negative Breast Cancer NDA approvals (if any), and product development activities comprising the technology, HR Positive/ HER2 Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

HR Positive/ HER2 Negative Breast Cancer Overview

A breast cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and progesterone, which suggests the cancer cells receive signals from these hormones that promote their growth. Cancer tissue is also tested for HER-2 proteins, or receptors, that help control the growth and repair of breast cells in which HER-2-negative breast cancers, have cells that contain little to no HER-2 protein, so they tend to grow more slowly and have a better outlook than HER-2-positive cancers The breast cancer subtype HR+/HER2- is the most common subtype with an age-adjusted rate of 87.4 new cases per 100,000 women, based on 2015–2019 cases.

 

Find out more about HR Positive/ HER2 Negative Breast Cancer Therapeutics Assessment @ HR Positive/ HER2 Negative Breast Cancer Preclinical and Discovery Stage Products

 

HR Positive/ HER2 Negative Breast Cancer Emerging Drugs Profile

  • Camizestrant: AstraZeneca
  • Dato-DXd: Daiichi Sankyo, Inc.
  • CX-2009: CytomX Therapeutics
  • RGT-419B: Regor Therapeutics

 

HR Positive/ HER2 Negative Breast Cancer Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing therapies for HR Positive/ HER2 Negative Breast Cancer. The HR Positive/ HER2 Negative Breast Cancer companies which have their HR Positive/ HER2 Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

 

DelveInsight’s HR Positive/ HER2 Negative Breast Cancer pipeline report covers around 53+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

HR Positive/ HER2 Negative Breast Cancer Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies @ HR Positive/ HER2 Negative Breast Cancer Clinical Trials Assessment

 

Scope of the HR Positive/ HER2 Negative Breast Cancer Pipeline Report

  • Coverage- Global
  • HR Positive/ HER2 Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • HR Positive/ HER2 Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • HR Positive/ HER2 Negative Breast Cancer Companies- Regor Therapeuics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo Inc., Tyme, Inc., Seagen Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co. Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche, and others.
  • HR Positive/ HER2 Negative Breast Cancer Pipeline Therapies- CX-2009, CX-072, Dato-DXd, Capecitabine, Gemcitabine, OP-1250, Ribociclib, Alpelisib, Palbociclib 125mg, Cyclophosphamide, Doxorubicin, and others

 

Dive deep into rich insights for new drugs for HR Positive/ HER2 Negative Breast Cancer Treatment, Visit @ HR Positive/ HER2 Negative Breast Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. HR Positive/ HER2 Negative Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. HR Positive/ HER2 Negative Breast Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Dato-DXd: Daiichi Sankyo, Inc.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CX-2009: CytomX Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. RGT-419B: Regor Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. HR Positive/ HER2 Negative Breast Cancer- Unmet Needs
  21. HR Positive/ HER2 Negative Breast Cancer- Market Drivers and Barriers
  22. Appendix

 

For further information on the HR Positive/ HER2 Negative Breast Cancer Pipeline therapeutics, reach out to HR Positive/ HER2 Negative Breast Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HR Positive/ HER2 Negative Breast Cancer Pipeline, Clinical Trials Developments and Companies 2023

Marginal Zone Lymphoma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023

DelveInsight’s, “Marginal Zone Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Marginal Zone Lymphoma Pipeline Report

  • DelveInsight’s Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
  • The leading companies working in the Marginal Zone Lymphoma Market include Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., Gamida Cell, BeiGene, Loxo Oncology, and others
  • Promising Marginal Zone Lymphoma Pipeline Therapies in the various stages of development include Tafasitamab, Orelabrutinib, EO2463, MIL62, Loncastuximab, NX-2127, LP-168, Zandelisib, BR101801, BP1002, Mosunetuzumab, CLR 131, IBI376, Pirtobrutinib, Zilovertamab vedotin, TG-1801, VAY736, ADI-001, CDX-1140, PSB202, Acalabrutinib, axicabtagene ciloleucel, Obinutuzumab, Cirmtuzumab, Nemtabrutinib, Lenalidomide, IGM-2323, Epcoritamab, GDA-201, BGB-16673,  LOXO-305, and others.
  • December 2023: Nurix Therapeutics Inc. announced a study of Phase 1 clinical trials for NX-5948. This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
  • December 2023: John Lister announced a study of Phase 2 clinical trials for Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous). This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
  • December 2023: Fred Hutchinson Cancer Center announced a study of Phase 1 & 2 clinical trials for Cyclophosphamide and Leukapheresis. The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory).
  • December 2023: Beigene announced a study of Phase 1 & 2 clinical trials for BGB-10188, Zanubrutinib and Tislelizumab. The purpose of this study is to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell malignancies; in combination with zanubrutinib in participants with R/R follicular lymphoma (FL), R/R mantle cell lymphoma (MCL) or R/R diffuse large B-cell lymphoma (DLBCL); and in combination with tislelizumab in participants with advanced solid tumors.

 

Request a sample and discover the recent advances in Marginal Zone Lymphoma Treatment Drugs @ Marginal Zone Lymphoma Pipeline Outlook Report

 

In the Marginal Zone Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Marginal Zone Lymphoma NDA approvals (if any), and product development activities comprising the technology, Marginal Zone Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Marginal Zone Lymphoma Overview

Marginal zone lymphoma (MZL) is the second most common indolent non-Hodgkin’s lymphoma (iNHL). There are three types of marginal zone lymphomas: the extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT or gastric GALT), the splenic MZL, and the nodal MZL. EMZL can originate at virtually any extranodal site and arises in organs that normally lack lymphoid tissue (eg, stomach, intestine, thyroid, lung, and skin).

 

Find out more about Marginal Zone Lymphoma Therapeutics Assessment @ Marginal Zone Lymphoma Preclinical and Discovery Stage Products

 

Marginal Zone Lymphoma Emerging Drugs Profile

  • Tafasitamab: Incyte Corporation
  • Amdizalisib (HMPL-689): HUTCHMED
  • Orelabrutinib: InnoCare Pharma
  • EO2463: Enterome

 

Marginal Zone Lymphoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies that are developing therapies for Marginal Zone Lymphoma. The Marginal Zone Lymphoma companies have their Marginal Zone Lymphoma drug.

 

DelveInsight’s Marginal Zone Lymphoma pipeline report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued and inactive candidates

 

Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Marginal Zone Lymphoma Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Learn more about the emerging Marginal Zone Lymphoma Pipeline Therapies @ Marginal Zone Lymphoma Clinical Trials Assessment

 

Scope of the Marginal Zone Lymphoma Pipeline Report

  • Coverage- Global
  • Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Marginal Zone Lymphoma Companies- Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., Gamida Cell, BeiGene, Loxo Oncology, and others
  • Marginal Zone Lymphoma Pipeline Therapies- Tafasitamab, Orelabrutinib, EO2463, MIL62, Loncastuximab, NX-2127, LP-168, Zandelisib, BR101801, BP1002, Mosunetuzumab, CLR 131, IBI376, Pirtobrutinib, Zilovertamab vedotin, TG-1801, VAY736, ADI-001, CDX-1140, PSB202, Acalabrutinib, axicabtagene ciloleucel, Obinutuzumab, Cirmtuzumab, Nemtabrutinib, Lenalidomide, IGM-2323, Epcoritamab, GDA-201, BGB-16673,  LOXO-305, and others.

 

Dive deep into rich insights for new drugs for Marginal Zone Lymphoma Treatment, Visit @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Marginal Zone Lymphoma Executive Summary
  3. Marginal Zone Lymphoma Overview
  4. Marginal Zone Lymphoma Pipeline Therapeutics
  5. Marginal Zone Lymphoma Pipeline Therapeutic Assessment
  6. Marginal Zone Lymphoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tafasitamab: Incyte Corporation
  9. Mid Stage Products (Phase II)
  10. Orelabrutinib: InnoCare Pharma
  11. Early Stage Products (Phase I/II)
  12. EO2463: Enterome
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Marginal Zone Lymphoma Key Companies
  17. Marginal Zone Lymphoma Key Products
  18. Marginal Zone Lymphoma- Unmet Needs
  19. Marginal Zone Lymphoma- Market Drivers and Barriers
  20. Marginal Zone Lymphoma- Future Perspectives and Conclusion
  21. Marginal Zone Lymphoma Analyst Views
  22. Marginal Zone Lymphoma Key Companies
  23. Appendix

 

For further information on the Marginal Zone Lymphoma Pipeline therapeutics, reach out to Marginal Zone Lymphoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Marginal Zone Lymphoma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023